In the latest trading session, 3.43 million NLS Pharmaceutics Ltd (NASDAQ:NLSP) shares changed hands as the company’s beta touched -0.52. With the company’s most recent per share price at $2.58 changed hands at -$0.45 or -14.90% at last look, the market valuation stands at $6.37M. NLSP’s current price is a discount, trading about -843.41% off its 52-week high of $24.34. The share price had its 52-week low at $3.00, which suggests the last value was -16.28% down since then. When we look at NLS Pharmaceutics Ltd’s average trading volume, we note the 10-day average is 47300.0 shares, with the 3-month average coming to 215.82K.

Analysts gave the NLS Pharmaceutics Ltd (NLSP) stock a consensus recommendation rating of Buy, calculated at a mean rating of 3.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended NLSP as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. NLS Pharmaceutics Ltd’s EPS for the current quarter is expected to be 0.

NLS Pharmaceutics Ltd (NASDAQ:NLSP) trade information

Instantly NLSP was in red as seen in intraday trades today. With action -27.57%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -89.07%, with the 5-day performance at -27.57% in the red. However, in the 30-day time frame, NLS Pharmaceutics Ltd (NASDAQ:NLSP) is -28.38% down. Looking at the short shares, we see there were 55986.0 shares sold at short interest cover period of 0.11 days.

NLS Pharmaceutics Ltd (NASDAQ:NLSP)’s Major holders

ARMISTICE CAPITAL, LLC holds the second largest percentage of outstanding shares, with 6.0535% or 2.31 million shares worth $0.5 million as of 2024-06-30.

With 359.0 shares estimated at $917.0 under it, the former controlled 0.01% of total outstanding shares.